Anti-amyloid antibody
Anti-amyloid-β antibody
- Antibody to aggregated amyloid-β — protofibrils (lecanemab) or deposited plaque (donanemab) — cleared through microglia
- Slows decline modestly in early symptomatic Alzheimer’s; does not reverse it
- ARIA (edema, microhemorrhage) is the mechanism’s cost — MRI monitoring; APOE ε4 homozygotes carry the highest risk
- Antibody to aggregated amyloid-β — protofibrils (lecanemab) or deposited plaque (donanemab) — cleared through microglia
- Slows decline modestly in early symptomatic Alzheimer’s; does not reverse it
- ARIA (edema, microhemorrhage) is the mechanism’s cost — MRI monitoring; APOE ε4 homozygotes carry the highest risk
Drugs with this mechanism (2)
- Donanemab — Plaque-targeting anti-amyloid antibody for early Alzheimer disease; treatment can stop after PET clearance.
- Lecanemab — Anti-amyloid protofibril antibody that modestly slows early Alzheimer disease; ARIA limits use.
All mechanisms · Open Anti-amyloid antibody in the interactive console ↗